Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000506998
Ethics application status
Approved
Date submitted
12/05/2011
Date registered
16/05/2011
Date last updated
23/09/2014
Type of registration
Retrospectively registered

Titles & IDs
Public title
Epirubicin-Paclitaxel-Cyclophosphamide Methotrexate Fluorouracil (E-T-CMF) versus Epirubicin-Cyclophosphamide Methotrexate Fluorouracil (E-CMF) as adjuvant chemotherapy in high risk patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group (HE10/97)
Scientific title
High-risk patients with operable breast cancer treated with Epirubicin followed by Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) or Epirubicin followed by Cyclophosphamide-Methotrexate-Fluorouracil (E-CMF) as adjuvant chemotherapy to investigate the effect of the treatment on disease-free survival and overall survival.
Secondary ID [1] 262142 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
high-risk operable breast cancer 265820 0
Condition category
Condition code
Cancer 265974 265974 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
epirubicin [110 milligram/square meter (mg/m2) intravenously infused over 30 minutes] every 2 weeks for 3 cycles followed by 3 cycles of paclitaxel (250 mg/m2, intravenously infused over 3 hours) every 2 weeks and 3 cycles of CMF (cyclophosphamide; 840 mg/m2, methotrexate; 57 mg/m2 and fluorouracil; 840 mg/m2 intravenously infused over 30 minutes) every 2 weeks
Intervention code [1] 264560 0
Treatment: Drugs
Comparator / control treatment
epirubicin (110 mg/m2, intravenously infused over 30 minutes) every 2 weeks for 4 cycles followed by 4 cycles of CMF (cyclophosphamide; 840 mg/m2, methotrexate; 57 mg/m2 and fluorouracil; 840 mg/m2, intravenously infused over 30 minutes) every 2 weeks.
Control group
Active

Outcomes
Primary outcome [1] 266728 0
Disease-Free Survival (DFS).
DFS was measured from randomization until local recurrence, distant relapse or death from the disease without relapse.
Timepoint [1] 266728 0
5 years from study initiation
Secondary outcome [1] 276269 0
Translational Research of Human Epidermal growth factor Receptor 2 (HER2) status and other biomarkers like: basal marker, angiogenesis, BRCA1 etc.
We collect paraffin embedded tumor tissue at baseline.
The samples are assessed by immunohistochemistry, Fluorescent in situ hybridization (FISH), Chromogenic In Situ Hybridization (CISH), polymerase chain reaction (PCR).
Timepoint [1] 276269 0
Results are correlated with outcome at 5 years and 8 years
Secondary outcome [2] 276313 0
Overall Survival (OS).
OS was measured from the date of randomization until death from any cause.
Timepoint [2] 276313 0
5 years from study initiation
Secondary outcome [3] 276314 0
Acute toxicity
Timepoint [3] 276314 0
Toxicity is assessed by laboratory evaluation of hematology and biochemistry, physical examination etc.
1 month since the last administration of chemotherapy for acute toxicity
Secondary outcome [4] 276315 0
Quality of Life. We use the EUroQol (EQ-5D) evaluation questionnaire
Timepoint [4] 276315 0
Baseline-End of Chemotherapy

Eligibility
Key inclusion criteria
-Histologically-confirmed epithelial cancer of the mammary gland. -Premenopausal patients with T1 to T2 classification with histologically-confirmed invasion of axillary lymph nodes (N1 classification) or T3 and N0 or N1 classification. -Postmenopausal patients with T1 to T2 classification and > 4 positive axillary nodes or T3 and N0 or N1 classification. - White Blood Cells (WBC) >4x10^9/litre, platelets >100 x10^9 /litre. -Serum creatinine, Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyltranspeptidase (gamma-GT), serum bilirubin < = 1.3 milligram/milliliter (mg/ml) or inside the normal range of the participating hospital. -Performance status (World Health Organization) 0 or 1. -Age >= 18 years. -Previous surgical treatment: Either radical surgery (i.e. total, radical or modified radical mastectomy), or, for a partial mastectomy, a histologically confirmed sane margin of 2 cm or more and the results of the axillary node dissection available. -Time from surgery 2 to 4 weeks -Informed consent of the patient according to the dispositions of the Helsinki convention and its Tokyo and Venice amendments and to individual institutional policy.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Previous antitumor chemotherapy or radiation
- History of myocardial infarction within the previous 12 months or heart failure (including cardiac insufficiency controlled by digitalis and diuretics) or arrhythmias requiring medication or uncontrolled arterial hypertension (Blood Pressure>= 200/110 millimetres of mercury (mmHg). In high risk patients a normal baseline left ventricular ejection fraction (LVEF) should be demonstrated by Multi Gated Acquisition Scan (MUGA) scan or echocardiogram (ECHO).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
11/06/1997
Actual
11/06/1997
Date of last participant enrolment
Anticipated
Actual
2/11/2000
Date of last data collection
Anticipated
Actual
Sample size
Target
600
Accrual to date
Final
Recruitment outside Australia
Country [1] 3583 0
Greece
State/province [1] 3583 0

Funding & Sponsors
Funding source category [1] 265042 0
Other Collaborative groups
Name [1] 265042 0
Hellenic Cooperative Oncology Group
Country [1] 265042 0
Greece
Primary sponsor type
Other Collaborative groups
Name
Hellenic Cooperative Oncology Group
Address
Hatzikostandi 18, 11524, Athens
Country
Greece
Secondary sponsor category [1] 264143 0
None
Name [1] 264143 0
Address [1] 264143 0
Country [1] 264143 0

Ethics approval
Ethics application status
Approved

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32593 0
Prof George Fountzilas, MD
Address 32593 0
"Papageorgiou" Hospital, Nea Efkarpia, 564 29, Thessaloniki
Country 32593 0
Greece
Phone 32593 0
+30 2313323959
Fax 32593 0
+30 2313683136
Email 32593 0
[email protected]
Contact person for public queries
Name 15840 0
Eleni Papakostaki
Address 15840 0
18, Hatzikostandi str, 11524, Athens
Country 15840 0
Greece
Phone 15840 0
+30 2106912520
Fax 15840 0
Email 15840 0
[email protected]
Contact person for scientific queries
Name 6768 0
Prof. George Fountzilas, MD
Address 6768 0
"Papageorgiou" Hospital, Nea Efkarpia, 564 29, Thessaloniki
Country 6768 0
Greece
Phone 6768 0
+30 2313323959
Fax 6768 0
Email 6768 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: A study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.2012https://dx.doi.org/10.1186/bcr3354
Dimensions AIDifferential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel2012https://doi.org/10.1371/journal.pone.0037946
Dimensions AIHER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy2012https://doi.org/10.1186/1479-5876-10-10
EmbaseEvaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.2013https://dx.doi.org/10.1186/1471-2407-13-163
Dimensions AIPrognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)2013https://doi.org/10.1371/journal.pone.0070634
Dimensions AIalphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies2014https://doi.org/10.1186/1472-6890-14-28
Dimensions AIDifferential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes2014https://doi.org/10.1371/journal.pone.0091407
EmbasePrognostic significance of VEGFC and VEGFR1 mRNA expression according to HER2 status in breast cancer: A study of primary tumors from patients with high-risk early breast cancer participating in a randomized hellenic cooperative oncology group trial.2015
Dimensions AIAssociation of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group2017https://doi.org/10.1186/s12967-017-1134-7
Dimensions AIEvaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy2017https://doi.org/10.1016/j.tranon.2017.05.006
N.B. These documents automatically identified may not have been verified by the study sponsor.